Abstract
Breast cancer is the most common malignant tumor among women often involving the toxicity of conventional chemotherapy alongside organ-specific side effects. As immunotherapeutic agents in anti-tumor, new immune checkpoints are constantly being dug and discovered. The role of immune checkpoint inhibitors in the process of tumor immune evasion has assumed increasing significance. Currently, clinical research outcomes on immunotherapy for breast cancer vary, reflecting diverse efficacy profile of immune checkpoints. This article provides an overview of immune checkpoint suppression therapy, and track the evolving research and therapeutic application of immune checkpoints related to breast cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
